Foliglurax
![]() | |
Clinical data | |
---|---|
Other names | DT2331; PXT-002331; PXT-2331 |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H23N3O3S |
Molar mass | 421.52 g·mol−1 |
3D model (JSmol) | |
| |
|
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[1][2] As of July 2017, it is in phase II clinical trials.[1]
![](http://upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Foliglurax_skeletal.svg/250px-Foliglurax_skeletal.svg.png)
The other tautomeric form of foliglurax.
References[]
- ^ a b "Foliglurax - Lundbeck". Adis Insight. Springer Nature Switzerland AG.
- ^ Jankovic J, Aguilar LG (August 2008). "Current approaches to the treatment of Parkinson's disease". Neuropsychiatric Disease and Treatment. 4 (4): 743–57. doi:10.1016/j.bmcl.2017.07.075. PMC 2536542. PMID 19043519.
Categories:
- Benzopyrans
- Experimental drugs
- MGlu4 receptor agonists
- Morpholines
- Nitroso compounds
- Thienopyridines
- Nervous system drug stubs